Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $23,480.00 in Stock

Posted by Scott Moore on Mar 16th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00. Following the sale, the president now directly owns 2,835,260 shares of the company’s stock, valued at $33,285,952.40. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00.
On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total value of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total value of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $12.11 on Friday. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $19.00. The stock’s 50 day simple moving average is $11.27 and its two-hundred day simple moving average is $12.31.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after purchasing an additional 1,996 shares in the last quarter. Northern Trust Corp boosted its position in Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Barclays PLC boosted its position in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Wells Fargo & Company MN boosted its position in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after buying an additional 918 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They issued an “outperform” rating on the stock.

View Our Latest Stock Analysis on Gyre Therapeutics

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.